Your patient has chronic kidney disease (CKD). This handout provides information about dosing adjustments if antidepressants are required. The information is provided as a guide. If you have a patient specific question, please contact your patient’s nephrologist or care team.

2023年5月8日 · Selective serotonin reuptake inhibitors (SSRIs) are considered generally safe and are the most commonly prescribed medication for people with chronic kidney...

2024年5月7日 · Despite observational studies suggesting potential safety concerns, sertraline, a selective serotonin reuptake inhibitor (SSRI), was shown in two 12-week randomized trials to be safe, although associated with an increased risk of nausea and vomiting, among patients with CKD and kidney failure who were treated with hemodialysis (10, 11).

2012年10月2日 · Drug pharmacokinetics are altered in CKD, which may necessitate dose adjustment. We aimed to systematically review available evidence of the pharmacokinetics, efficacy and safety of antidepressant drugs when used in patients with CKD3 to CKD5 (CKD3-5).

2017年1月1日 · Depression is well known to affect adults with end-stage renal disease (ESRD), in part attributed to psychosocial and biologic changes that accompany dialysis. 1, 2 Recent studies have shown that patients with chronic kidney disease (CKD) who are not on dialysis have rates of depression up to 3 times higher than those in the general population ...

Selective serotonin reuptake inhibitors (SSRIs) have been a mainstay of depression treatment for decades. 7 Most large trials of SSRIs and other antidepressants have been performed in physically healthy persons, and studies among persons with physical comorbidities have been smaller and at risk of publication bias. 8 Studies of antidepressant ...

Clinical guidelines suggest treatment with antidepressant medication (with SSRIs as first‐line) in adults with CKD who meet diagnostic criteria for depression, based on observational studies and limited evidence of harm (ERBP 2012).

2023年9月24日 · Several randomized studies have demonstrated the efficacy of antidepressants in treating depression in those with reduced kidney function. The preferred choice among healthcare practitioners is often selective serotonin reuptake inhibitors (SSRIs), such as Sertraline or Fluoxetine, due to their extensive research and safety profile.

We discuss the rationale and design of the CAST study, the largest placebo-controlled trial aimed to establish safety and efficacy of a SSRI in the acute phase treatment of CKD patients with MDD. Keywords: depression, chronic kidney disease, sertraline, randomized trial, treatment.

2021年1月1日 · The first-line antidepressants for use in CKD and ESRD are the selective serotonin reuptake inhibitors (SSRIs).36, 37 They exert their main therapeutic effect by blocking presynaptic recycling of serotonin, leading to increased concentrations of serotonin in synaptic clefts. 38 SSRIs are generally preferred as first-line agents for MDD over ...